HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.

Jason W.D. Hearn,Christopher Sweeney,Nima Almassi,Chad A. Reichard,Chandana A. Reddy,Brian P. Hobbs,David Frazier Jarrard,Yu-Hui Chen,Robert Dreicer,Jorge A. Garcia,Michael A. Carducci,Robert S. DiPaola,Nima Sharifi

HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.

2019

Jason W.D. Hearn
Christopher Sweeney
Nima Almassi
Chad A. Reichard
Chandana A. Reddy
Brian P. Hobbs
David Frazier Jarrard
Yu-Hui Chen
Robert Dreicer
Jorge A. Garcia
Michael A. Carducci
Robert S. DiPaola
Nima Sharifi

5020Background: The HSD3B1(1245A > C) variant allele, whose frequency varies by race, encodes a missense sequence that stabilizes the rate-limiting enzyme responsible for extragonadal androgen synt...

Keywords:

Prostate cancer
Randomized controlled trial
Androgen deprivation therapy
HSD3B1
Pathology
Oncology
Medicine
Internal medicine
low volume
Androgen
Missense mutation
Extragonadal

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations